Escherichia coli Lipopolysaccharide (LPS) Antibody (Biotin)
377€ (200 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Escherichia coli Lipopolysaccharide (LPS) Antibody (Biotin)
category
Primary Antibodies
provider
Abbexa
reference
abx274404
tested applications
ELISA, IHC
Description
Lipopolysaccharide (LPS) Antibody (Biotin) is a mouse monoclonal antibody (
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: Escherichia coli Lipopolysaccharide (LPS) Immunogen: abx165772 - LPS conjugated to OVA, from E.coli o55:B5 |
| Host | Mouse |
| Reactivity | General |
| Assay Type | Concentration: 1 mg/ml |
| Recommended Dilution | IHC (Predicted): 5-20 µg/ml, IF/ICC (Predicted): 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Biotin |
| Isotype | IgG2b Kappa |
| Clone ID | Z563 |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 200 µl |
| Size 2 | 1 ml |
| Form | Liquid |
| Tested Applications | ELISA, IHC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-15 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | LPS |
| Background | Antibody anti-LPS |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-negative bacteria, playing a crucial role in the structural integrity of bacterial cells and acting as a potent activator of the immune system. Composed of lipid A, a core oligosaccharide, and an O-antigen polysaccharide, LPS is a critical factor in bacterial pathogenicity. Lipid A is the bioactive component that triggers immune responses by binding to the Toll-like receptor 4 (TLR4) complex on immune cells, leading to the activation of nuclear factor-kappa B (NF-κB) and the release of pro-inflammatory cytokines such as IL-6 and TNF-alpha. While LPS is essential for host defense, its excessive activation can result in septic shock, characterized by systemic inflammation, organ failure, and high mortality. Therapeutic strategies targeting LPS-TLR4 signaling pathways are being explored to manage sepsis and other inflammatory conditions.
Related Products
